3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: Precision H+,K+-ATPase Inhibition for Gastric Acid Secretion Research

Executive Summary. 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845, supplied by APExBIO) is a highly potent H+,K+-ATPase inhibitor with an IC50 of 5.8 μM under in vitro conditions (DMSO, 25°C) and demonstrates robust antiulcer activity by suppressing gastric acid secretion (IC50 for histamine-induced acid formation: 0.16 μM) [APExBIO product page]. The compound is supplied at ≥98% purity (HPLC, NMR-verified), has low water/ethanol solubility but dissolves ≥17.27 mg/mL in DMSO, and is intended strictly for research use. Its mechanism and selectivity support reproducible modeling of gastric acid-related disorders, and it is not suitable for clinical or diagnostic applications. Benchmarking studies confirm its utility in translational research and mechanistic dissection of H+,K+-ATPase signaling. [Kong et al., 2025]

Biological Rationale

Gastric acid secretion is regulated by the H+,K+-ATPase (proton pump) located in the parietal cell membrane. Overactivity of this pump is implicated in the pathogenesis of peptic ulcer disease, gastroesophageal reflux, and other gastric acid-related disorders. Inhibitors of H+,K+-ATPase are essential tools for probing these disease models and for dissecting the gastric acid secretion pathway. High-precision inhibitors such as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide are valuable for research due to their potency, selectivity, and reproducibility [limaprostresearch.com]. This compound enables laboratory scientists to model acid secretion and antiulcer effects in cell and animal models, facilitating translational insights into gastric and hepatic disorders.

Mechanism of Action of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is a non-covalent, competitive inhibitor targeting the H+,K+-ATPase enzyme. The compound binds to the catalytic subunit of the enzyme, preventing the final exchange of protons (H+) from parietal cells with potassium ions (K+) from the gastric lumen. This inhibition reduces gastric acid secretion at the source. In vitro, its inhibitory effect is quantifiable with an IC50 of 5.8 μM (buffered DMSO, 25°C) [APExBIO]. In cellular assays, the IC50 for blocking histamine-induced acid formation is 0.16 μM, demonstrating greater potency in situ. The selectivity of this compound minimizes off-target effects, supporting mechanism-driven research. For further mechanistic detail and comparison to related inhibitors, see Advancing Translational Research, which this article updates with new evidence on selectivity and pathway integration.

Evidence & Benchmarks

• Demonstrates H+,K+-ATPase inhibition with an in vitro IC50 of 5.8 μM in DMSO at 25°C (APExBIO).
• Blocks histamine-induced gastric acid formation with an IC50 of 0.16 μM in cellular models (APExBIO).
• Supplied at ≥98% purity, confirmed by HPLC and NMR analysis (certificate of analysis provided by manufacturer) (APExBIO).
• Storage at -20°C preserves compound integrity; limited stability in solution (>24 h at room temperature not recommended) (APExBIO).
• Insoluble in water and ethanol; high solubility in DMSO (≥17.27 mg/mL) for assay preparation (APExBIO).
• Validated in translational and mechanistic research workflows for antiulcer activity and gastric acid secretion studies (dppiv.com).
• Supports modeling of gastric acid-related disorders in preclinical animal models (limaprostresearch.com).
• Not suitable for diagnostic or therapeutic use in humans (APExBIO).

Applications, Limits & Misconceptions

This compound is optimized for preclinical research in gastric acid secretion, antiulcer activity studies, and the proton pump inhibition pathway. It is suitable for in vitro, ex vivo, and in vivo animal model experiments. The product is not intended for diagnostic, therapeutic, or clinical applications in humans. Misconceptions about its use in direct clinical translation should be avoided. Its high selectivity and potency make it ideal for benchmarking new H+,K+-ATPase inhibitors and studying the molecular mechanisms of acid secretion. For practical scenarios and troubleshooting in experimental workflows, see Harnessing 3-(quinolin-4-ylmethylamino)..., which this article extends by detailing updated stability and application parameters.

Common Pitfalls or Misconceptions

• Not suitable for long-term storage in solution form; compound degrades at room temperature beyond 24 h.
• Insoluble in most aqueous or alcoholic solvents; must be dissolved in DMSO at concentrations ≤17.27 mg/mL.
• For research use only; not for diagnostic or therapeutic use in humans or animals.
• Potency and selectivity are assay-dependent; IC50 values may vary with buffer, temperature, and substrate.
• Does not directly address neuroinflammation, though gastric acid and gut-brain axis research are related fields.

Workflow Integration & Parameters

For optimal experimental design, dissolve the compound in anhydrous DMSO to achieve a stock concentration of ≥17.27 mg/mL. Prepare working dilutions immediately before use. Store stock material at -20°C, protected from light and moisture. Do not store diluted solutions for more than 24 h at room temperature. For in vitro studies, titrate concentrations from 0.01 μM to 100 μM depending on assay sensitivity. In in vivo models, reference published protocols for dose selection and administration route. Robust purity (≥98%) and validated batch documentation support reproducibility in translational workflows [dppiv.com]. This article clarifies the workflow integration steps outlined in Applied Workflows for H+,K+-ATPase Inhibitor... by adding updated stability and handling data.

Conclusion & Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (APExBIO, A2845) provides a precise, validated tool for dissecting gastric acid secretion and antiulcer mechanisms in preclinical research. Its defined mechanism, high purity, and reproducible potency enable robust modeling of gastric acid-related disorders and facilitate the development of novel H+,K+-ATPase inhibitors. Future research will likely extend its use to systems-level studies linking gastric, hepatic, and neurological disease models, as outlined in recent translational reviews [Kong et al., 2025]. For detailed product information, refer to the A2845 kit page.